newsfilter
← Latest News
GlobeNewswire·

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update

Mural's lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expected in 1H 2025 A